Determinants of longer time from HIV result to enrollment in publicly funded care and treatment in California by race/ethnicity and behavioral risk

AIDS Patient Care and STDs

Volumn 16, Issue 11, 2002, Pages 555-565

  Molitor, Fred ^a   Walsh, Rachel M ^b   Leigh, J Paul ^b  

^a ETR ASSOCIATES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BEHAVIOR MODIFICATION; ETHNIC GROUP; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; COMMUNITY HEALTH CENTERS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HEALTH BEHAVIOR; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; RISK FACTORS; STATE HEALTH PLANS; TIME FACTORS; UNITED STATES;

EID: 0036851684     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729102761041119     Document Type: Article

References (19)

1. Fleming PL, Wortley PM, Karon JM, DeCock KM, Janssen RS. Tracking the HIV epidemic: Current issues, future challenges. Am J Public Health 2000;90:1037-1041.
2. Samet JH, Freeberg KA, Stein MD, et al. Time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998;158:734-740.
3. Hisada M, O'Brien TR, Rosenburg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. J Infect Dis 2000;181:1475-1478.
4. Centers for Disease Control and Prevention. 1997 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. MMWR Morb Mortal Wkly Rep 1997;46:1-45.
5. Carpenter CC, Fischl MA, Hammer SG, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-1969.
6. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991;6:35-40.
7. Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med 1997;12:150-157.
8. Diaz T, Chu SY, Sorvillo F, et al. Differences in participation in experimental drug trials among persons with AIDS. J Acquir Immune Defic Syndr Hum Retroviral 1995;10:562-568.
9. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-768.
10. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. Health Serv Res 2000;35:389-416.
11. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002;346:1373-1382.
12. Turner BJ, Cunningham WE, Duan N, et al. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000;160:2614-2622.
13. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: The long-term non-presenter. AIDS 2001;15:77-85.
14. Bindman AB, Osmond D, Hecht FM, et al. Multistate evaluation to anonymous HIV testing and access to medical care. JAMA 1998;280:1416-1420.
15. Duan N, Manning WG Jr, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Business Econ 1983;1:115-126.
16. Leigh JP, Fries JF. Health habits and medical costs. Inquiry 1992;29:44-54.
17. Solomon L, Stein M, Flynn C, et al. Health services use by urban women with or at risk for HIV-1 infection: The HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:253-261.
18. Solomon L, Frank R, Vlahov D, Astemborski J. Utilization of health services in a cohort of intraveneous drug users with known HIV-1 serostatus. Am J Public Health 1991;81:1285-1290.
19. Mor V, Fleishman JA, Dresser M, Piette J. Variation in health service use among HIV-infected patients. Med Care 1992;30:17-29.